<br>        Inclusion Criteria:<br><br>          -  Men and women, 18 years of age or older.<br><br>          -  Subjects with Chronic Phase Ph+ CML.<br><br>          -  Subjects have not been treated with imatinib at a dose >600 mg/day.<br><br>          -  Subjects developed resistance to disease while receiving an imatinib dose 400-600<br>             mg/day.<br><br>          -  Able to tolerate imatinib at the highest dose the subject had received in the past.<br><br>          -  Demonstrate adequate renal and hepatic function.<br><br>          -  Women of childbearing potential must have a negative serum or urine pregnancy test,<br>             must be using an adequate method of contraception.<br><br>        Exclusion Criteria:<br><br>          -  Women who are unwilling or unable to use an acceptable method to avoid pregnancy for<br>             the entire study period for a least 1 month before and at least 3 months after the<br>             completion of the study.<br><br>          -  Women using a prohibited contraceptive method.<br><br>          -  Women who are pregnant or breastfeeding.<br><br>          -  Men whose sexual partners are women who are of childbearing potential, and who are<br>             unwilling or unable to use an acceptable method to avoid pregnancy of his partner for<br>             the entire study period as outlined above.<br><br>          -  Prior treatment with imatinib at a dose >600 mg/day.<br><br>          -  Subjects who have previously identified specific BCR-ABL mutations.<br><br>          -  Previous diagnosis of accelerated phase or blast crisis CML.<br><br>          -  Intolerance to imatinib at any dose.<br><br>          -  Subjects who are eligible and willing to undergo transplantation during the screening<br>             period.<br><br>          -  Serious uncontrolled medical disorder or active infection.<br><br>          -  Uncontrolled or significant cardiovascular disease.<br><br>          -  Uncontrolled hypertension.<br><br>          -  Dementia or altered mental status.<br><br>          -  Evidence of organ dysfunction.<br><br>          -  Use of imatinib within 7 days.<br><br>          -  Use of interferon or cytarabine within 14 days.<br><br>          -  Use of a targeted small molecule anticancer agent within 14 days.<br><br>          -  Subjects taking certain medications that are accepted to have a risk of causing<br>             Torsades de Pointes.<br><br>          -  Subjects taking medications that irreversibly inhibit platelet function or<br>             anticoagulants.<br><br>          -  Prior therapy with BMS-354825.<br>      ;<br>        Inclusion Criteria:<br><br>          -  Men and women, 18 years of age or older.<br><br>          -  Subjects with Chronic Phase Ph+ CML.<br><br>          -  Subjects have not been treated with imatinib at a dose >600 mg/day.<br><br>          -  Subjects developed resistance to disease while receiving an imatinib dose 400-600<br>             mg/day.<br><br>          -  Able to tolerate imatinib at the highest dose the subject had received in the past.<br><br>          -  Demonstrate adequate renal and hepatic function.<br><br>          -  Women of childbearing potential must have a negative serum or urine pregnancy test,<br>             must be using an adequate method of contraception.<br><br>        Exclusion Criteria:<br><br>          -  Women who are unwilling or unable to use an acceptable method to avoid pregnancy for<br>             the entire study period for a least 1 month before and at least 3 months after the<br>             completion of the study.<br><br>          -  Women using a prohibited contraceptive method.<br><br>          -  Women who are pregnant or breastfeeding.<br><br>          -  Men whose sexual partners are women who are of childbearing potential, and who are<br>             unwilling or unable to use an acceptable method to avoid pregnancy of his partner for<br>             the entire study period as outlined above.<br><br>          -  Prior treatment with imatinib at a dose >600 mg/day.<br><br>          -  Subjects who have previously identified specific BCR-ABL mutations.<br><br>          -  Previous diagnosis of accelerated phase or blast crisis CML.<br><br>          -  Intolerance to imatinib at any dose.<br><br>          -  Subjects who are eligible and willing to undergo transplantation during the screening<br>             period.<br><br>          -  Serious uncontrolled medical disorder or active infection.<br><br>          -  Uncontrolled or significant cardiovascular disease.<br><br>          -  Uncontrolled hypertension.<br><br>          -  Dementia or altered mental status.<br><br>          -  Evidence of organ dysfunction.<br><br>          -  Use of imatinib within 7 days.<br><br>          -  Use of interferon or cytarabine within 14 days.<br><br>          -  Use of a targeted small molecule anticancer agent within 14 days.<br><br>          -  Subjects taking certain medications that are accepted to have a risk of causing<br>             Torsades de Pointes.<br><br>          -  Subjects taking medications that irreversibly inhibit platelet function or<br>             anticoagulants.<br><br>          -  Prior therapy with BMS-354825.<br>      ;<br>        Inclusion Criteria:<br><br>          -  Men and women, 18 years of age or older.<br><br>          -  Subjects with Chronic Phase Ph+ CML.<br><br>          -  Subjects have not been treated with imatinib at a dose >600 mg/day.<br><br>          -  Subjects developed resistance to disease while receiving an imatinib dose 400-600<br>             mg/day.<br><br>          -  Able to tolerate imatinib at the highest dose the subject had received in the past.<br><br>          -  Demonstrate adequate renal and hepatic function.<br><br>          -  Women of childbearing potential must have a negative serum or urine pregnancy test,<br>             must be using an adequate method of contraception.<br><br>        Exclusion Criteria:<br><br>          -  Women who are unwilling or unable to use an acceptable method to avoid pregnancy for<br>             the entire study period for a least 1 month before and at least 3 months after the<br>             completion of the study.<br><br>          -  Women using a prohibited contraceptive method.<br><br>          -  Women who are pregnant or breastfeeding.<br><br>          -  Men whose sexual partners are women who are of childbearing potential, and who are<br>             unwilling or unable to use an acceptable method to avoid pregnancy of his partner for<br>             the entire study period as outlined above.<br><br>          -  Prior treatment with imatinib at a dose >600 mg/day.<br><br>          -  Subjects who have previously identified specific BCR-ABL mutations.<br><br>          -  Previous diagnosis of accelerated phase or blast crisis CML.<br><br>          -  Intolerance to imatinib at any dose.<br><br>          -  Subjects who are eligible and willing to undergo transplantation during the screening<br>             period.<br><br>          -  Serious uncontrolled medical disorder or active infection.<br><br>          -  Uncontrolled or significant cardiovascular disease.<br><br>          -  Uncontrolled hypertension.<br><br>          -  Dementia or altered mental status.<br><br>          -  Evidence of organ dysfunction.<br><br>          -  Use of imatinib within 7 days.<br><br>          -  Use of interferon or cytarabine within 14 days.<br><br>          -  Use of a targeted small molecule anticancer agent within 14 days.<br><br>          -  Subjects taking certain medications that are accepted to have a risk of causing<br>             Torsades de Pointes.<br><br>          -  Subjects taking medications that irreversibly inhibit platelet function or<br>             anticoagulants.<br><br>          -  Prior therapy with BMS-354825.<br>      ;<br>        Inclusion Criteria:<br><br>          -  Men and women, 18 years of age or older.<br><br>          -  Subjects with Chronic Phase Ph+ CML.<br><br>          -  Subjects have not been treated with imatinib at a dose >600 mg/day.<br><br>          -  Subjects developed resistance to disease while receiving an imatinib dose 400-600<br>             mg/day.<br><br>          -  Able to tolerate imatinib at the highest dose the subject had received in the past.<br><br>          -  Demonstrate adequate renal and hepatic function.<br><br>          -  Women of childbearing potential must have a negative serum or urine pregnancy test,<br>             must be using an adequate method of contraception.<br><br>        Exclusion Criteria:<br><br>          -  Women who are unwilling or unable to use an acceptable method to avoid pregnancy for<br>             the entire study period for a least 1 month before and at least 3 months after the<br>             completion of the study.<br><br>          -  Women using a prohibited contraceptive method.<br><br>          -  Women who are pregnant or breastfeeding.<br><br>          -  Men whose sexual partners are women who are of childbearing potential, and who are<br>             unwilling or unable to use an acceptable method to avoid pregnancy of his partner for<br>             the entire study period as outlined above.<br><br>          -  Prior treatment with imatinib at a dose >600 mg/day.<br><br>          -  Subjects who have previously identified specific BCR-ABL mutations.<br><br>          -  Previous diagnosis of accelerated phase or blast crisis CML.<br><br>          -  Intolerance to imatinib at any dose.<br><br>          -  Subjects who are eligible and willing to undergo transplantation during the screening<br>             period.<br><br>          -  Serious uncontrolled medical disorder or active infection.<br><br>          -  Uncontrolled or significant cardiovascular disease.<br><br>          -  Uncontrolled hypertension.<br><br>          -  Dementia or altered mental status.<br><br>          -  Evidence of organ dysfunction.<br><br>          -  Use of imatinib within 7 days.<br><br>          -  Use of interferon or cytarabine within 14 days.<br><br>          -  Use of a targeted small molecule anticancer agent within 14 days.<br><br>          -  Subjects taking certain medications that are accepted to have a risk of causing<br>             Torsades de Pointes.<br><br>          -  Subjects taking medications that irreversibly inhibit platelet function or<br>             anticoagulants.<br><br>          -  Prior therapy with BMS-354825.<br>